Researchers Identify SALL1 as a Tumor Suppressor in Breast Cancer with a Role in E-Cadherin Regulation

Researchers at the German Cancer Research Center (DKFZ) and the MD Anderson Cancer Center used Cellecta's shRNA DECIPHER Libraries for an in vivo genetic screen that identified SALL1 as a breast cancer tumor suppressor that plays a role in E-cadherin regulation (Article).

E-cadherin (CDH1) has been shown to have a role in epithelial-to-mesenchymal (EMT) transition in breast cancer. Silencing of SALL1 via promoter hypermethylation has also been shown to be associated with breast cancer. In the current publication, researchers show that inhibition of SALL1 is correlated with decreased CDH1 expression, as well as changes in other gene expression associated with EMT.

Michael Boettcher's group at DKFZ transduced the SUM-149 breast cancer cell line with the DECIPHER short-hairpin RNA (shRNA) library Human Module 1, which targets approximately 5,000 human genes. Each gene is targeted by 5-6 shRNAs, and the sequences are barcoded for easy detection by NGS. They then injected the transduced cells into immunosuppressed mice and waited for tumors to develop. After harvesting the tumors they analyzed the genomic DNA using NGS to see which genes have tumor suppressor activities in vivo.

They identified 16 candidate tumor suppressor genes, and chose to focus the rest of their study on SALL1. SALL1 belongs to the zinc finger transcription factor family and has recently been implicated in breast cancer. In their RNAi screen, two shRNA constructs were identified that target SALL1. Each of these SALL1-targeting shRNAs was subcloned into an expression vector and transduced into the SUM-149 breast cancer cell line, as well as into several other breast cancer cell lines. The transduced SUM-149 cells were then injected into immunosuppressed mice. Expression of the shRNA to SALL1 decreased the tumor-free survival period in the immunosuppressed mice and increased the number of mitotically active tumor cells compared to control tumor cells.

To determine what other genes are affected by decreased SALL1 expression, the group analyzed SUM-149 cells expressing shSALL1 by microarray. Approximately 200 genes were significantly changed in the study. In particular, several genes involved in EMT were affected, including decreased CDH1, and increased CDH2, VIM, and MSN. They also found increased amounts of CTGF and CYR61, which are critical in breast cancer carcinogenesis, and decreased RARRES1 and RARRES3, which are known tumor suppressor genes.

The researchers discovered that decreased levels of SALL1 correlated with other changes typically associated with breast cancer. For example, SUM-149 cells expressing shSALL1 were shown to migrate more in wound healing assays, suggesting they were more metastatic, and had higher numbers of cells with the CD44+/CD24-/low phenotype—a marker associated with cancer stem cells. Also, patient breast cancer samples that had high amounts of SALL1 expressed correlated with higher relapse-free survival, overall survival, metastasis-free survival, and tumor-free survival.

This study provides an excellent example of how in vivo pooled RNAi screens can be used to elucidate cellular pathways associated with cancer pathology.

DKFZ Facility in Heidelberg, Germany where SALL1 identified as tumor suppressor in breast cancer

A list of all Cellecta collaboration and customer references is available on our website at /resources/publications/.

Leave a comment

Comments will be approved before showing up.

Also in Cellecta Blog & News

Inducible Cas9 Expression in a Single Lentiviral Vector

Introducing Inducible Cas9 Expression in a Single Lentiviral Vector to make cells capable of high Cas9 expression for a limited time during which CRISPR-mediated targeted rearrangements can occur, and then shut off Cas9 expression for downstream assays with the modified cells.
Read More
Insertion of 10X Genomics' Capture Sequences Does Not Affect HEAT-Tracr sgRNA Efficacy

Perturb-Seq or CROP-Seq screens make use of single-cell RNA-Sequencing in conjunction with a pooled CRISPR library to identify transcriptional changes and, by implication, activation or deactivation of cellular pathways related to phenotypic changes produced by specific sgRNA-mediated gene knockouts.
Read More
Core Population of Cancer Stem Cells Mediates Therapeutic Resistance in Tumors

Researchers at MD Anderson Cancer Center recently used a Cellecta CloneTracker Barcode Library to label patient-derived xenograft (PDX) cells and establish a stable population of aggressive tumorigenic cells with a specific set of barcodes. With this population of barcoded tumorigenic clones, the investigators...
Read More